ArticleScientific reports2026
The association of SPISE with cardiometabolic multimorbidity and stroke in middle-aged and older adults: a nationwide prospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin resistance is a key driver of cardiometabolic diseases, including stroke. The single-point insulin sensitivity estimator (SPISE) is a novel non-invasive marker of insulin sensitivity calculated from fasting triglycerides, high-density lipoprotein cholesterol and body mass index. However, its association with cardiometabolic multimorbidity (CMM) and stroke in the general population remains unclear. This study aimed to investigate the prospective association between SPISE and incident CMM and stroke in middle-aged and older Chinese adults. This prospective cohort study included 6,624 participants aged 45 years and older from the China Health and Retirement Longitudinal Study (CHARLS) with follow-up through 2020. SPISE was calculated using a validated formula. Cox proportional hazards regression models, restricted cubic spline analyses, Kaplan-Meier survival curves, and subgroup analyses were employed to evaluate the associations between SPISE and incident CMM and stroke. Over a median follow-up of 114 months, 632 participants (9.5%) developed incident stroke, and 696 (10.5%) developed CMM. In fully adjusted multivariable models, each one-unit increase in the baseline SPISE index was significantly associated with a 10% decreased risk of incident stroke (HR = 0.90, 95% CI: 0.86-0.94) and a 15% decreased risk of CMM (HR = 0.85, 95% CI: 0.81-0.89). Compared to the low SPISE reference group (< 6.61), individuals in the high SPISE category (≥ 6.61) exhibited a 27% lower risk of stroke (HR = 0.73, 95% CI: 0.62-0.88) and a 48% lower risk of CMM (HR = 0.52, 95% CI: 0.43-0.62). Restricted cubic spline analyses confirmed strictly linear, inverse dose-response relationships between SPISE and both outcomes. These protective associations remained structurally robust across diverse demographic and clinical subgroups, with significant effect modification identified solely for baseline heart disease and age concerning the CMM outcome. Higher SPISE is independently and linearly associated with reduced risks of incident CMM and stroke in middle-aged and older Chinese adults. As a simple, low-cost marker derived from routine clinical measurements, SPISE may serve as a practical tool for cardiometabolic risk stratification in primary care settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.